Published on November 18, 2009 at 5:59 AM
Research and Markets (http://www.researchandmarkets.com/research/44c77e/chronic_myelogenou) has announced the addition of Decision Resources, Inc.'s new report "Chronic Myelogenous Leukemia: New Targeted Therapies Take Aim at Gleevec" to their offering.
Chronic myelogenous leukemia (CML) is a rare blood cancer; nonetheless, CML treatments garner substantial revenues. Despite recent advances in the treatment of this disease (most notably, targeted therapeutics such as Novartis's Gleevec/Glivec [imatinib]), significant unmet needs remain because certain segments of the CML patient population are intolerant of or become resistant to existing therapies. Emerging therapies that focus on the unmet needs of current therapeutics have a good chance of replicating Gleevec's success.
Questions Answered in This Report
Properly diagnosing CML is an integral part of choosing an effective treatment.
- How is CML diagnosed?
- What role does genetic testing play in developing and deploying drugs for CML?
- What are the symptoms of CML?
Treatment options for CML are more targeted today than in recent history.
- How was CML previously treated?
- Why have targeted therapies proved to be better CML treatment options?
Despite treatment advances, opportunities remain for emerging CML agents.
- What are these opportunities?
- Are the opportunities potentially lucrative enough to motivate drug developers?
Scope
- Disease overview: disease causes and indicators, physical and genetic symptoms, diagnosis, classification, epidemiology, and disease progression.
- Current CML therapies: chemotherapy, interferon-alpha, targeted therapies, stem cell therapy.
- Emerging CML therapies: targeted therapies, therapies focused on particular disease mutations.
- Market outlook: 2008 CML market sales, opportunities for current and emerging CML therapies.
Key Topics Covered:
Executive Summary
- Strategic Considerations
- Stakeholder Implications
http://www.researchandmarkets.com/research/44c77e/chronic_myelogenou
7bf27f4a-8638-4658-857c-939d6b386a81|0|.0
Posted in: Device / Technology News
Tags: Blood Cancer, Cancer, Cell, Chemotherapy, Epidemiology, Genetics, Gleevec, Leukemia, Omacetaxine, Sprycel, Stem Cell